Sign Up Today and Learn More About InterVenn Stock
Invest in or calculate the value of your shares in InterVenn or other pre-IPO companies through EquityZen's platform.
InterVenn Stock (INTV)
InterVenn Biosciences identifies, quantifies, and classifies Glycoproteomic and other PTM signals found in human blood and tissue.
About InterVenn Stock
Founded
2017
Headquarters
South San Francisco, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum or plasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides. It was founded in 2017 and headquartered in Redwood City, California.
InterVenn Press Mentions
Stay in the know about the latest news on InterVenn
Biomarkers for determining a cancer disease state, response to immuno-oncology, …
patents • Apr 14, 2024
Identification and use of glycopeptides as biomarkers for diagnosis and …
patents • Apr 14, 2024
Sample preparation for glycoproteomic analysis that includes diagnosis of …
patents • Apr 14, 2024
De novo glycopeptide sequencing
patents • Apr 14, 2024
Diagnosis of colorectal cancer using targeted quantification of site-specific …
patents • Apr 14, 2024
Investors in InterVenn
Discover investors in InterVenn stock and explore their portfolio companies
InterVenn Management
Leadership team at InterVenn
Scientific Co-Founder
Carolyn Bertozzi
Co-Founder and CEO
Aldo Carrascoso
Join now and verify your accreditation status to gain access to:
- InterVenn current valuation
- InterVenn stock price
- Available deals in InterVenn and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading InterVenn Stock
How to invest in InterVenn stock?
Accredited investors can buy pre-IPO stock in companies like InterVenn through EquityZen funds. These investments are made available by existing InterVenn shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell InterVenn stock?
Shareholders can sell their InterVenn stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
